Cargando…

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab

Despite the recent emergence of targeted therapeutic options, there are still unmet needs concerning moderate-to-severe atopic dermatitis treatment. This review aims to discuss the OX40-OX40L pathway as a therapeutic target for the treatment of atopic dermatitis. OX40 and OX40L are two checkpoint mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lé, Ana Maria, Torres, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787630/ https://www.ncbi.nlm.nih.gov/pubmed/36559247 http://dx.doi.org/10.3390/pharmaceutics14122753

Ejemplares similares

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis
por: ELSNER, Julie Sophie Hohwü, et al.
Publicado: (2020)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response
Publicado: (1996)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
por: Li, Fei, et al.
Publicado: (2016)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Hsa_circ_0000652 Aggravates Inflammation by Activation of Macrophages and Enhancement of OX40/OX40L Interaction in Ankylosing Spondylitis
por: Song, Minkai, et al.
Publicado: (2021)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

OX40-OX40L Interaction Promotes Proliferation and Activation of Lymphocytes via NFATc1 in ApoE-Deficient Mice
por: Yan, Jinchuan, et al.
Publicado: (2013)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
por: Ming, Siqi, et al.
Publicado: (2021)

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
por: An, Jingnan, et al.
Publicado: (2019)

An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma
por: Deng, Zhuoya, et al.
Publicado: (2022)

Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism
por: Dong, Q., et al.
Publicado: (2013)

New pathways in immune stimulation: targeting OX40
por: Alves Costa Silva, Carolina, et al.
Publicado: (2020)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis
por: Gourh, Pravitt, et al.
Publicado: (2010)

Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis
por: Laustsen, Julie K, et al.
Publicado: (2014)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

OX40: a win–win path to tumor immunity
por: Sedwick, Caitlin
Publicado: (2008)

OX40 is required for regulatory T cell–mediated control of colitis
por: Griseri, Thibault, et al.
Publicado: (2010)

OX40 Facilitates Control of a Persistent Virus Infection
por: Boettler, Tobias, et al.
Publicado: (2012)

Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells
por: Reuter, Dajana, et al.
Publicado: (2015)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Breaking Immunological Tolerance through OX40 (CD134)
por: Bansal-Pakala, Pratima, et al.
Publicado: (2001)

The Role of OX40 (CD134) in T-Cell Memory Generation
por: Weinberg, Andrew D.
Publicado: (2010)

Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy
por: Shin, Chang-Ae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ub4hkvg4jm04nu930qjtmioa2p